• West Pharmaceutical Services named Michel Lagarde president, CEO, board member effective Aug. 31, 2026.
• Lagarde succeeds Eric M. Green, set to retire as president, CEO, board chair on Aug. 31, 2026.
• Lead independent director Robert F. Friel to become board chair effective Aug. 31, 2026.
• Lagarde described as an experienced healthcare, life sciences executive to lead the company’s next growth phase.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. West Pharmaceutical Services Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606011630PR_NEWS_USPR_____NE73015) on June 01, 2026, and is solely responsible for the information contained therein.